NZ549125A - Anti-EpCAM immunoglobulins - Google Patents

Anti-EpCAM immunoglobulins

Info

Publication number
NZ549125A
NZ549125A NZ549125A NZ54912505A NZ549125A NZ 549125 A NZ549125 A NZ 549125A NZ 549125 A NZ549125 A NZ 549125A NZ 54912505 A NZ54912505 A NZ 54912505A NZ 549125 A NZ549125 A NZ 549125A
Authority
NZ
New Zealand
Prior art keywords
cancer
epcam
immunoglobulin
administration
days
Prior art date
Application number
NZ549125A
Other languages
English (en)
Inventor
Malte Peters
Mathias Locher
Nadja Prang
Cornelia Quadt
Original Assignee
Micromet Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Micromet Ag filed Critical Micromet Ag
Publication of NZ549125A publication Critical patent/NZ549125A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
NZ549125A 2004-02-13 2005-02-09 Anti-EpCAM immunoglobulins NZ549125A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/778,915 US20050180979A1 (en) 2004-02-13 2004-02-13 Anti-EpCAM immunoglobulins
PCT/EP2005/001307 WO2005080428A2 (en) 2004-02-13 2005-02-09 Anti-epcam immunoglobulins

Publications (1)

Publication Number Publication Date
NZ549125A true NZ549125A (en) 2008-09-26

Family

ID=34838270

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ549125A NZ549125A (en) 2004-02-13 2005-02-09 Anti-EpCAM immunoglobulins

Country Status (23)

Country Link
US (3) US20050180979A1 (enExample)
EP (2) EP1713830B1 (enExample)
JP (1) JP5220315B2 (enExample)
KR (1) KR101236224B1 (enExample)
CN (1) CN1976951B (enExample)
AT (1) ATE437186T1 (enExample)
AU (1) AU2005215874B2 (enExample)
BR (1) BRPI0507660A (enExample)
CA (1) CA2555694C (enExample)
DE (1) DE602005015544D1 (enExample)
DK (1) DK1713830T3 (enExample)
EA (1) EA011951B1 (enExample)
ES (1) ES2328159T3 (enExample)
IL (1) IL177069A (enExample)
MX (1) MXPA06008942A (enExample)
NO (1) NO339364B1 (enExample)
NZ (1) NZ549125A (enExample)
PL (1) PL1713830T3 (enExample)
PT (1) PT1713830E (enExample)
SI (1) SI1713830T1 (enExample)
UA (1) UA87128C2 (enExample)
WO (1) WO2005080428A2 (enExample)
ZA (1) ZA200606083B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070122406A1 (en) 2005-07-08 2007-05-31 Xencor, Inc. Optimized proteins that target Ep-CAM
EP2474822A1 (en) 2003-01-24 2012-07-11 University of Utah Methods of predicting mortality risk by determining telomere length
AU2007213920B2 (en) * 2006-02-09 2013-08-29 Amgen Research (Munich) Gmbh Treatment of metastatic breast cancer
DK2041181T3 (da) * 2006-06-08 2011-08-29 Helmholtz Zentrum Muenchen Specifikke proteaseinhibitorer og deres anvendelse i cancerterapi
EP1865001A1 (en) * 2006-06-08 2007-12-12 Gsf-Forschungszentrum Für Umwelt Und Gesundheit, Gmbh Specific protease inhibitors and their use in cancer therapy
EP2142570B1 (en) * 2007-04-04 2011-06-15 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Anti-epcam antibody and uses thereof
CA2748265C (en) 2008-12-22 2018-04-03 University Of Utah Research Foundation Monochrome multiplex quantitative pcr
EP2480687B1 (en) * 2009-09-21 2015-01-28 Paul Walfish Methods and compositions for the diagnosis and treatment of thyroid cancer
EP2819695B1 (en) * 2012-03-02 2018-06-27 Academia Sinica ANTI-EPITHELIAL CELL ADHESION MOLECULE (EpCAM) ANTIBODIES AND METHODS OF USE THEREOF
CN103387988B (zh) * 2012-09-24 2016-01-06 厦门大学 上皮细胞粘附分子的核酸适体EpCAM Ccut及其制备方法
EP2999800B1 (en) 2013-05-22 2019-09-25 Telomere Diagnostics Inc. Measures of short telomere abundance
CN103275226B (zh) * 2013-06-09 2017-08-29 中国科学技术大学 特异性抗人上皮细胞粘附分子（EpCAM）的单克隆抗体的制备、鉴定及应用
ES2728668T3 (es) * 2014-01-08 2019-10-28 Univ Leland Stanford Junior Terapia dirigida para el cáncer de pulmón de células pequeñas
CA2971169A1 (en) 2014-12-30 2016-07-07 Telomere Diagnostics, Inc. Multiplex quantitative pcr
AU2016358296B2 (en) * 2015-11-19 2020-05-21 Revitope Limited Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
KR20190038567A (ko) 2016-07-26 2019-04-08 테사 테라퓨틱스 피티이. 엘티디. 키메라 항원 수용체
WO2020018964A1 (en) 2018-07-20 2020-01-23 Fred Hutchinson Cancer Research Center Compositions and methods for controlled expression of antigen-specific receptors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5853697A (en) * 1995-10-25 1998-12-29 The United States Of America, As Represented By The Department Of Health & Human Services Methods of treating established colitis using antibodies against IL-12
BRPI9809391B8 (pt) * 1997-04-14 2021-05-25 Amgen Res Munich Gmbh processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica
US6855544B1 (en) * 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
US7605238B2 (en) * 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
DK1383785T3 (da) * 2001-05-03 2011-05-23 Merck Patent Gmbh Rekombinant tumorspecifikt antistof og anvendelse deraf
US20030175268A1 (en) * 2002-01-11 2003-09-18 Saint-Remy Jean-Marie R. Method and pharmaceutical composition for preventing and/or treating systemic inflammatory response syndrome
PL375064A1 (en) * 2002-05-20 2005-11-14 Abgenix, Inc. Treatment of renal carcinoma using antibodies against the egfr

Also Published As

Publication number Publication date
WO2005080428A2 (en) 2005-09-01
PL1713830T3 (pl) 2010-01-29
JP2008500277A (ja) 2008-01-10
JP5220315B2 (ja) 2013-06-26
DK1713830T3 (da) 2009-10-12
AU2005215874B2 (en) 2011-01-27
PT1713830E (pt) 2009-10-19
CN1976951B (zh) 2012-03-14
US20120294873A1 (en) 2012-11-22
ATE437186T1 (de) 2009-08-15
HK1096103A1 (en) 2007-05-25
ZA200606083B (en) 2007-10-31
WO2005080428A3 (en) 2005-11-10
SI1713830T1 (sl) 2009-10-31
EA200601386A1 (ru) 2007-06-29
NO20064136L (no) 2006-11-07
MXPA06008942A (es) 2007-01-26
AU2005215874A1 (en) 2005-09-01
US20050180979A1 (en) 2005-08-18
KR20070009988A (ko) 2007-01-19
IL177069A0 (en) 2006-12-10
US20070274982A1 (en) 2007-11-29
CA2555694A1 (en) 2005-09-01
KR101236224B1 (ko) 2013-02-22
BRPI0507660A (pt) 2007-07-17
UA87128C2 (ru) 2009-06-25
EA011951B1 (ru) 2009-06-30
NO339364B1 (no) 2016-12-05
EP2107071A2 (en) 2009-10-07
CA2555694C (en) 2013-04-16
EP1713830A2 (en) 2006-10-25
EP1713830B1 (en) 2009-07-22
EP2107071A3 (en) 2009-12-30
DE602005015544D1 (de) 2009-09-03
CN1976951A (zh) 2007-06-06
ES2328159T3 (es) 2009-11-10
IL177069A (en) 2010-11-30

Similar Documents

Publication Publication Date Title
US20120294873A1 (en) ANTI-EpCAM IMMUNOGLOBULINS
JP2021193096A (ja) Ｐｄ−１軸結合アンタゴニスト及び抗ｃｅａ／抗ｃｄ３二重特異性抗体を用いたｃｅａ陽性がんの治療方法
US20120117670A1 (en) Humanized axl antibodies
KR20190136076A (ko) 암 치료 방법에 사용하기 위한 인터루킨-2 면역접합체, cd40 작용제 및 임의적인 pd-1 축 결합 길항제
WO1994022478A1 (en) PREVENTION OF TUMORS WITH MONOCLONAL ANTIBODIES AGAINST $i(NEU)
US6733752B1 (en) Prevention of tumors with monoclonal antibodies against neu
CN114044827B (zh) 低adcc/cdc功能性单抗及其制备方法与应用
CN101365486A (zh) 使用抗egfr和抗her2抗体的联合治疗
CN112739716A (zh) 使用抗pd-1抗体与抗组织因子抗体-药物偶联物的组合治疗癌症的方法
EP2270053A1 (en) Humanized AXL antibodies
CN114340679A (zh) 用于治疗对pd-1/pd-l1信号传导抑制剂无应答的癌症的方法和药物
JP2023554422A (ja) がんの治療のための多重特異性抗体
CN112996540A (zh) 一种c-Met ADC在制备治疗c-Met激酶抑制剂耐药的疾病的药物中的用途
CN112672759B (zh) 抗程序性死亡配体-1(pd-l1)抗体的抗肿瘤用途
HK1096103B (en) Anti-epcam immunoglobulins
WO2023227115A1 (en) A method of treating solid tumor
CN114685674B (zh) 一种抗体融合蛋白及其应用
EP4470562A1 (en) Anti-pd-l1 antibody-containing pharmaceutical composition used in combination with anti-vegf antibodies and paclitaxel
KR20240038204A (ko) Pd-1에 특이적으로 결합하는 항체를 유효성분으로 포함하는 신경내분비 신생물의 예방 또는 치료용 약학 조성물
Garrett Peptide-based B-cell epitope vaccines targeting HER-2/neu
HK40052936A (en) Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
HK1249409B (en) 5-bromo-2,6-di-(1h-pyrazol-l-yl)pyrimidin-4-amine for use in the treatment of cancer
HK1249409A1 (en) 5-bromo-2,6-di-(1h-pyrazol-l-yl)pyrimidin-4-amine for use in the treatment of cancer

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 FEB 2016 BY CPA GLOBAL

Effective date: 20141230

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 FEB 2017 BY CPA GLOBAL

Effective date: 20151231

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 FEB 2018 BY CPA GLOBAL

Effective date: 20161230

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 FEB 2019 BY CPA GLOBAL

Effective date: 20180104

LAPS Patent lapsed